Today, Google Cloud announced the addition of two new clients who will highlight the benefits of its cloud computing infrastructure for the biotech sector.
One of the biggest gatherings on the biotech industry calendar, Bio-IT World, this week, is where the new alliances were unveiled. In order to maximize the potential of AI-powered digital pathology, Google Cloud announced that it is collaborating with Path AI Inc., an artificial intelligence startup, and TetraScience Inc., a provider of scientific data and AI cloud, in order to accelerate medication discovery and other forms of scientific research.
With its flagship product, the AISight Intelligent Management System, PathAI is a pioneer in the rapidly developing field of AI-powered pathology. Using its platform, AI models that can optimize the analysis of patient tissue samples for both diagnostic use cases and clinical trials may be developed and refined.
AISight IMS combines PathAI’s algorithms with external AI models to create a unified platform for image analysis and laboratory operations. Pathologists and researchers can use it to develop and implement potent biomarker quantification techniques that may enhance lab productivity and support diagnostic procedures like “disease staging and scoring.”
PathAI and Google Cloud are collaborating to expand the platform’s reach to other biopharma companies and labs across the globe. The business claims that in order to extend its digital pathology and algorithmic skills and assist its clients in processing petabytes of data for extensive biomarker discovery and clinical research, it will link its platform with Google Cloud’s globally dispersed infrastructure. By doing this, it will also give clients access to Google Cloud’s AI development resources, enabling them to refine their own AI algorithms.
Ryan Terry, managing director of Healthcare and Life Sciences at Google Cloud, stated, “We understand the urgent need within the biopharmaceutical industry for secure, scalable solutions in AI-driven drug discovery, laboratory operations, and biomarker quantification.”
TetraScience has developed a platform that converts unprocessed data in different formats from many sources into an AI-native format that data scientists and AI algorithms can easily use. Its platform is extensively employed in scientific AI research, assisting users in expediting the discovery and creation of novel medications and other medical treatments.
TetraScience claimed that by extending its platform to Google Cloud, researchers will be far more equipped to handle the massive amounts of complicated, unstructured, and proprietary data produced by lab informatics tools and equipment and combine it with data from other sources for study. Scientists are currently required to perform the majority of this labor by hand, making them into “human data integrators.”
TetraScience on Google Cloud enables the business to leverage Google’s capabilities to streamline data formatting and processing, saving scientists time on laborious, error-prone manual processes. Rather, scientists will have more time to concentrate on the real discoveries that come from their research. They will have the freedom to use the knowledge they have gathered from their study to invent and produce new medications and therapies that will enhance and extend people’s lives.
Scientists will be able to extract insights from “previously dead data” by merging Google Cloud’s Vertex AI with TetraScience’s platform. This should make it easier for researchers to find new drug candidates, create cutting-edge cell-based treatments, and digitize vital quality control procedures. The collaboration will also, according to the corporations, assist in bringing down the price of this kind of study.
According to Terry, issues with disjointed data and ineffective workflows have historically hindered scientific advancement. “By addressing these obstacles, this collaboration provides life sciences with the useful tools required to expedite drug discovery and development,” the speaker stated. Through the integration of TetraSciences’ established domain expertise with Google Cloud’s data and AI capabilities, our aim is to enable scientists to discover solutions to urgent health issues more quickly than in the past.
